Compare ELSE & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELSE | AKTX |
|---|---|---|
| Founded | 1968 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0M | 14.4M |
| IPO Year | N/A | N/A |
| Metric | ELSE | AKTX |
|---|---|---|
| Price | $4.40 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 2.9K | ★ 1.4M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $9,787,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.90 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $3.65 | $0.26 |
| 52 Week High | $5.50 | $1.73 |
| Indicator | ELSE | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 39.04 |
| Support Level | $4.48 | $0.26 |
| Resistance Level | $4.70 | $0.47 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 38.34 |
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.